Medication non-adherence remains a significant global healthcare challenge, contributing to preventable hospitalizations, poor treatment outcomes, and substantial economic burdens. In the United States alone, medication non-adherence is associated with over 125,000 preventable deaths each year and costs exceeding $100 billion annually (Say et al., 2026). Traditional adherence monitoring strategies, such as self-reported medication logs, pharmacy refill records, and smart pill bottles, are often limited by accuracy, patient engagement requirements, and environmental concerns. Recent research is exploring innovative solutions, including ingestible electronic devices, that could provide real-time verification of medication intake while minimizing patient burden. One of the most promising advancements in this space is the development of bioresorbable RFID capsules, which combine precise adherence monitoring with environmental sustainability.
Non-adherence is particularly common among patients with chronic conditions. Studies indicate that nearly half of patients with chronic illnesses fail to take medications as prescribed, leading to disease progression, increased hospitalization rates, and heightened mortality (Say et al., 2026). For example, inconsistent adherence to antiretroviral therapy in HIV patients can accelerate progression to AIDS, whereas consistent adherence can reduce HIV incidence by over fifty percent. Similarly, poor adherence in patients with type 2 diabetes mellitus contributes to preventable complications and significant healthcare costs. High-risk medications, such as opioids or immunosuppressants, also require close adherence monitoring to prevent misuse or adverse outcomes.
While the World Health Organization endorses directly observed therapy for certain diseases like tuberculosis, implementing these strategies at scale is costly and resource-intensive. Therefore, there is an urgent need for scalable, patient-friendly, and environmentally responsible monitoring systems that can provide accurate adherence data.
Existing adherence monitoring solutions can be categorized as indirect or direct methods. Indirect methods, such as patient self-reporting, pharmacy refill data, or smart pill bottles, often rely on patient compliance and may overestimate actual adherence. Direct methods include ingestible electronic sensors that provide biological evidence of drug intake or continuous physiological monitoring (Say et al., 2026).
Despite their promise, current electronic ingestion monitoring devices face several challenges. Many rely on non-degradable polymers and rigid electronic components that remain in the gastrointestinal tract after excretion. Over time, repeated ingestion of such devices raises safety concerns, including potential gastrointestinal injury. Moreover, the accumulation of electronic waste presents environmental issues, particularly in long-term or large-scale use. Additionally, these devices often require external batteries or retrieval after use, increasing logistical complexity and patient burden.
Bioresorbable electronics offer a transformative solution for medication adherence monitoring. By incorporating materials that naturally degrade within the gastrointestinal tract, these systems maintain the advantages of real-time monitoring while mitigating safety and environmental risks. Biodegradable polymers, transient conductive materials, and dissolvable sensors have been successfully used for physiological monitoring, wound healing, drug delivery, and temporary implants. However, their application in ingestible adherence monitoring has remained limited until recently (Say et al., 2026).
Natural polymers, particularly cellulose and its derivatives, are highly promising for bioresorbable ingestible devices. Cellulose is biocompatible, cost-effective, easy to process, and widely used in pharmaceuticals. Cellulose derivatives such as hydroxyethyl cellulose (HEC) can act as binders and functional coatings for biodegradable electronics, enabling controlled dissolution within the gastrointestinal environment.
To address these limitations, researchers developed SAFARI, which stands for Smart Adherence via FARaday cage And Resorbable Ingestible. This innovative platform combines a bioresorbable RFID tag with a cellulose-metal particle-based electromagnetic shielding coating. The shielding layer functions as a Faraday cage, blocking radiofrequency signals until the device reaches the target location in the gastrointestinal tract. Once the coating dissolves, the RFID tag becomes active, allowing healthcare providers to confirm ingestion events accurately (Say et al., 2026).
The SAFARI capsule is compatible with standard gelatin or hydroxypropyl methylcellulose (HPMC) capsules, making it easily adaptable for clinical use. The device’s RFID chip stores essential information such as drug dosage, serial number, and manufacturing data. When ingested, the coating dissolves in the stomach, activating the RFID signal. Healthcare professionals can then track medication ingestion via an external reader without requiring device retrieval or patient intervention.
The SAFARI platform is composed of several components. The RFID tag uses a zinc-based antenna bonded to a cellulose acetate substrate, supported by a biodegradable polyglycol sebacate (PGS) adhesive. The tag communicates with standard UHF RFID readers operating at 915 megahertz. The electromagnetic shielding layer consists of HEC mixed with biodegradable metal microparticles, such as molybdenum or tungsten, which provide high conductivity and effective radiofrequency blocking.
Extensive in vitro and in vivo testing demonstrated that the zinc antenna and metal coating dissolve within a few days under physiological conditions. The cellulose substrate gradually softens, facilitating safe passage through the gastrointestinal tract. Importantly, the materials used are generally recognized as safe (GRAS) and compatible with normal dietary exposure, minimizing risk to patients (Say et al., 2026).
The SAFARI capsules were tested in swine models due to their gastrointestinal similarity to humans. The capsules were administered endoscopically and monitored via external RFID readers positioned near the stomach. Upon ingestion, the electromagnetic shielding layer swelled and dissolved, exposing the RFID tag. The tag successfully transmitted data, confirming the ingestion event. X-ray imaging verified safe passage of the capsule components, and serum analysis showed no significant increase in zinc or molybdenum levels beyond normal dietary intake.
This testing demonstrated several key advantages. First, the passive RFID tag reliably communicated through gastric fluids, confirming its functionality in complex biological environments. Second, the materials completely degraded or passed safely, reducing long-term risk. Third, the system provides a non-invasive, real-time method to monitor medication adherence, which could improve patient outcomes and reduce healthcare costs (Say et al., 2026).
Bioresorbable RFID capsules offer multiple benefits over traditional adherence monitoring technologies:
The SAFARI platform is particularly suited for high-risk clinical populations, including patients with infectious diseases such as tuberculosis, HIV, and hepatitis C, where non-adherence can lead to drug resistance. It is also relevant for transplant patients and individuals with cardiovascular conditions who require strict adherence to medications like immunosuppressants or antiplatelet therapies. Beyond medication adherence, bioresorbable RFID technology may be applied to clinical trials, personalized therapy monitoring, and controlled drug delivery systems (Say et al., 2026).
Future developments may include battery-assisted RFID tags for extended detection range and integration with wearable readers such as chest patches or belts for continuous monitoring. User-centered design studies will be essential to ensure that these systems are acceptable, reliable, and effective in real-world settings.
SAFARI devices were designed with material safety in mind. Zinc and molybdenum are essential trace elements with well-characterized metabolic handling and low risk of toxicity at microgram-to-milligram doses. Serum analyses in swine models confirmed that device administration did not significantly alter trace metal levels. Additionally, prior studies indicate safe passage of small RFID chips through the gastrointestinal tract without retention or tissue damage (Say et al., 2026). These findings support the feasibility of repeated or long-term use in adherence monitoring programs.
Despite promising results, several challenges remain. The biodegradation rate must be carefully controlled to ensure timely signal activation while preventing premature dissolution. Variations in stomach acidity and motility among patients may affect coating dissolution and signal reliability. Scaling up production of bioresorbable RFID capsules will require optimization of ink formulations, coating methods, and quality control processes.
Future research will explore chronic exposure modeling, pharmacokinetics, and integration with digital health systems. Development of battery-assisted or energy-harvesting tags may extend detection range and support continuous monitoring. Furthermore, patient-centric studies will help optimize reader placement, usability, and adherence workflows to maximize clinical benefit.
Bioresorbable RFID capsules represent a significant advancement in medication adherence monitoring, providing a safe, environmentally sustainable, and clinically adaptable solution. By combining biodegradable materials with advanced RFID technology, SAFARI enables real-time verification of medication intake without imposing additional burdens on patients or healthcare providers. Early in vivo studies confirm safety, effectiveness, and feasibility, highlighting the potential for wide-scale clinical application. As the technology evolves, it may redefine the standard of care for patients requiring strict adherence to critical medications, ultimately improving therapeutic outcomes and reducing healthcare costs.
Source:
Disclaimer: This blog is intended for informational purposes only and does not constitute medical advice. Readers should consult a qualified healthcare professional for diagnosis, treatment, or guidance on medication adherence.
